1-3 of 3
Patrick M. Dillon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

Patrick M. Dillon, Gina R. Petroni, Bethany J. Horton, Christopher A. Moskaluk, Paula M. Fracasso, Michael G. Douvas, Nikole Varhegyi, Snjezana Zaja-Milatovic, Christopher Y. Thomas
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4138–4145.
https://doi.org/10.1158/1078-0432.CCR-16-2942
Published: 01 August 2017
View article titled, A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
Open the PDF for A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67

Bojana Jovanović, Ingrid A. Mayer, Erica L. Mayer, Vandana G. Abramson, Aditya Bardia, Melinda E. Sanders, M. Gabriela Kuba, Monica V. Estrada, J. Scott Beeler, Timothy M. Shaver, Kimberly C. Johnson, Violeta Sanchez, Jennifer M. Rosenbluth, Patrick M. Dillon, Andres Forero-Torres, Jenny C. Chang, Ingrid M. Meszoely, Ana M. Grau, Brian D. Lehmann, Yu Shyr, Quanhu Sheng, Sheau-Chiann Chen, Carlos L. Arteaga, Jennifer A. Pietenpol
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4035–4045.
https://doi.org/10.1158/1078-0432.CCR-16-3055
Published: 01 August 2017
View article titled, A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Open the PDF for A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67 in another window
Includes: Supplementary data
Journal Articles

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

Patrick J. Roberts, Jerry E. Usary, David B. Darr, Patrick M. Dillon, Adam D. Pfefferle, Martin C. Whittle, James S. Duncan, Soren M. Johnson, Austin J. Combest, Jian Jin, William C. Zamboni, Gary L. Johnson, Charles M. Perou, Norman E. Sharpless
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5290–5303.
https://doi.org/10.1158/1078-0432.CCR-12-0563
Published: 30 September 2012
View article titled, Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
Open the PDF for Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models in another window
Includes: Supplementary data